Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART

Treatment with chimeric antigen receptor-T cell (CAR-T) is successful in patients who have not responded to chemotherapy or bone marrow transplantation but it may provoke side effects and long-term complications. Early and specific side effects include cytokine release syndrome and neurological toxicity. In addition, there are also late side effects. …

neutrophil count
cancer chemotherapy
multiple myeloma
cytopenia
  • 0 views
  • 01 May, 2022
  • 1 location
A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease

This is a multicenter study to assess the safety and efficacy of taliglucerase alfa (60 units/kg) in previously untreated subjects of any age with Type 3 GD. Subjects will receive an infusion of taliglucerase alfa every 2 weeks for 12 months. Subjects who tolerate the infusions well, and who are …

  • 0 views
  • 06 Jun, 2022
  • 3 locations
Symptom Identification and Management in Patients With Hematological Malignancy During Follow-up Care

The aim is to study the effect of a systematic approach to symptom identification and management with disease specific and clinically developed PRO (HM-PRO) with a 12 month follow up in outpatient care in patients with chronic hematological malignancy.

  • 0 views
  • 31 May, 2021
  • 1 location
Enhanced Palliative Care in MDS and AML

Objectives The purpose of this study is to evaluate the impact of enhanced haematology palliative care services to the most symptomatic group of blood cancer patients, namely myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). Hypothesis to be tested: To test whether early integration of dedicated palliative care will improve …

leukemia
Accepts healthy volunteers
myeloid leukemia
hematologic malignancy
cancer
  • 0 views
  • 24 Feb, 2022
  • 1 location
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Background Allogeneic hematopoietic stem cell transplant involves taking blood stem cells from a donor and giving them to a recipient. The transplants are used to treat certain diseases and cancers. Researchers want to see if the transplant can treat VEXAS Syndrome. Objective To see if stem cell transplants can be …

mycophenolate mofetil
fludarabine
x-rays
busulfan
total body irradiation
  • 0 views
  • 14 Jun, 2022
  • 1 location
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

patients with MDS (Myelodysplastic Syndrome) and mutated IDH1 patients will be treated with AG120 (IDH1 inhibitor)

azacitidine
ejection fraction
bone marrow procedure
blast cells
cytopenia
  • 7 views
  • 14 Feb, 2022
  • 2 locations
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

patients with MDS (Myelodysplastic Syndrome) and mutated IDH2 patients will be treated with AG221 (IDH2 inhibitor)

cell transplantation
filgrastim
granulocyte colony stimulating factor
azacitidine
ejection fraction
  • 4 views
  • 15 Feb, 2022
  • 2 locations
Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)

The immune system has offensive and defensive capacities. In bone marrow transplantation, offensive cells in the donor grafts may attack host's organs, leading to a complication known as Graft versus Host Disease (GVDH). At present, patients receive steroid treatment to combat this tricky situation. Nevertheless, some patients do not respond …

  • 0 views
  • 07 May, 2021
  • 2 locations
ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors

ATG based conditioning regimen in HLA related allogeneic hematopoietic stem cell transplantation for aggressive T-cell tumors: multi-center, open, randomized controlled clinical study

  • 0 views
  • 21 Jan, 2021
  • 1 location
Post IVIG Medication in Children With Immune Thrombocytopenia

This study is a single hospital system, single-arm year-long pilot to evaluate the feasibility of enrolling children with ITP who are receiving IVIG for treatment of disease to a scheduled post-infusion medication for 72 hours following IVIG infusion. This year-long feasibility pilot will test the (1) feasibility of enrollment and …

blood tests
thrombocytopenia
igiv
treatment regimen
  • 0 views
  • 31 Oct, 2021
  • 1 location